
EBV Latent membrane protein 2 329-337, LLWTLVVLL
Description
About EBV Latent membrane protein 2 329-337, LLWTLVVLL
The Epstein-Barr Virus (EBV) (strain AG876) Latent membrane protein 2 Peptide (IEDB: 37960) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Latent membrane protein Peptide, H-LLWTLVVLL-OH (Uniprot: Q1HVJ2 aa: 329-337) from JPT is produced under strict quality control and quality management.
EBV Latent membrane protein 2 329-337, LLWTLVVLL - Specifications
- Peptide sequence: H-LLWTLVVLL-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection, Arthritis, Infectious mononucleosis
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for EBV Latent membrane protein 2 329-337, LLWTLVVLL
References:
Read References with JPT’s Antigen Peptides
EBV Latent membrane protein 2 329-337, LLWTLVVLL has been described in:
Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy., J Immunol, 1997 (PMID: 9120290)
Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis., Clin Exp Immunol, 2003 (PMID: 12653848)
Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires., Immunogenetics, 2015 (PMID: 25502872)
Documentation
Documentation for EBV Latent membrane protein 2 329-337, LLWTLVVLL
Properties
Properties of EBV Latent membrane protein 2 329-337, LLWTLVVLL
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Arthritis, Infection, Infectious mononucleosis |
Layout: | Freeze-dried in glass vial |
Organism: | Epstein-Barr Virus (EBV) |
Protein Name: | Latent membrane protein |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to EBV Latent membrane protein 2 329-337, LLWTLVVLL
Information | Values |
---|---|
Sequence: | H-LLWTLVVLL-OH |
Specifications: | 9mer peptide as TFA salt |